Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. - sprookjes - yvandenbroek - TriplyDB

Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.

Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.

http://www.wikidata.org/entity/Q35170702

about

Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates Crystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design Implications Structure and Immunogenicity of a Peptide Vaccine, Including the Complete HIV-1 gp41 2F5 Epitope Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 Plant-based anti-HIV-1 strategies: vaccine molecules and antiviral approaches.Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140 Screening the interactions between HIV-1 neutralizing antibodies and model lipid surfaces.Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12 Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins.Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1.Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41 Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition.Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.Diversification of specificity after maturation of the antibody response to the HIV gp41 epitope ELDKWA.Phages and HIV-1: from display to interplay.Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.Neutralisation of HIV-1 cell-cell spread by human and llama antibodies.The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D Genetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state.The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.Thermodynamic analysis of the binding of 2F5 (Fab and immunoglobulin G forms) to its gp41 epitope reveals a strong influence of the immunoglobulin Fc region on affinity.Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex.Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12.Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L Assembly of human immunodeficiency virus (HIV) antigens on bacteriophage T4: a novel in vitro approach to construct multicomponent HIV vaccines.Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system.Identifiable biomarker and treatment development using HIV-1 long term non-progressor sera.

P2860

Q24531479-C3170351-5AAF-43D4-8D0F-111FB939AA30 Q24561905-9504709C-BEC9-49AB-86B7-65A734506851 Q27022055-C83EDA73-9650-4A31-B3AD-AF368507FB87 Q27489000-EF9B911D-11D1-4074-9F48-0759BD4F7F9B Q27657377-F53CE76B-853B-4D34-8655-E1CE6563B61A Q27681352-04D7EBA2-F27D-45E6-BC4B-6F3106C98792 Q28075274-92815C1B-E883-4960-B6AE-63E6E298B9D8 Q28387636-0AAAC4DF-4D63-4957-9F9D-AF8CF08A50C6 Q29619512-844DB6C7-F6F5-4695-829A-418B958480E7 Q30392083-0C3058C1-F1B9-4D0C-854B-B5F1BA85612C Q30431941-D74AA798-2EAA-4EF0-858E-4F8BA71C76C0 Q30451941-00063CCE-57F6-4422-A118-DE15D060209D Q30701127-08D5F891-3FFF-40C4-A106-C032C99024FD Q30706865-2F4FDF41-A916-4197-BD38-3CC7516A10D9 Q31016954-28DD9340-8F4C-458E-911E-6CE9D2BB829B Q31016969-5F17B499-E5F6-49BB-AEA8-5C538764CDA3 Q33417195-FD3D1E63-DC70-4FAC-BB07-B7EAF1E8CD02 Q33783353-C5A8CA6A-EBD2-4B01-A876-B8D6FF599EEE Q33786382-74E4D1E4-78DF-40DC-A94B-B5BDC2160198 Q33807129-EDD12294-EE80-4884-A273-68AF186CB4EC Q33842152-A8F3F29D-92C9-4475-A4DF-0F7CBDF5751B Q33850612-2D04FF78-F241-4D7D-8D05-8AE879773E11 Q33852768-35ACB27F-2B8E-43C5-91EF-F7A1EE3486AF Q34163633-FD4231B5-6CB6-43BA-A2A5-270F6559B366 Q34273397-A4A2E4DC-CD50-4E31-ABB2-03617C3771BC Q34292765-DF4654C3-9949-4C1A-AD41-C2878B3F56AD Q34304203-D3C0DA74-D486-4935-AE42-2A9CFD4EA924 Q34317025-F8C00523-3E43-43AA-91EA-0448BD13113A Q34323863-896CF6BA-4F99-4F02-A451-6971C3ADCEE0 Q34342264-CC352235-E018-4420-A421-8BB5E6D19251 Q34342352-1A48F756-1C5D-47D8-AE96-B905994A5528 Q34348303-7AEEB9C1-0C39-4369-9464-6DF69685B2E6 Q34359035-ADDE3184-931C-4B8A-A4D7-5E39310A2D19 Q34389587-7EF3D23D-D889-4956-BF35-42DD6CBE7497 Q34709433-828EBA26-FC17-4170-BAFB-DD91C0AF8017 Q34781840-7571877B-4D0B-4CC0-9EE3-98211D5A5EB6 Q35012462-1ED44582-B28E-4FD1-AE08-FFDD60910E8B Q35023762-BBC1BBA3-4BB1-4A69-95B7-03AFCC70B91A Q35060140-C231F846-9963-4A14-8D8A-AFE246282E13 Q35540731-198CE270-93B6-4C68-9600-020DE1D51599

P2860

Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.

http://www.wikidata.org/entity/Q35170702

description

1994 nî lūn-bûn

@nan

1994 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

1994 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

1994年の論文

@ja

1994年論文

@yue

1994年論文

@zh-hant

1994年論文

@zh-hk

1994年論文

@zh-mo

1994年論文

@zh-tw

1994年论文

@wuu

name

Neutralization of divergent hu ...... p41 human monoclonal antibody.

@ast

Neutralization of divergent hu ...... p41 human monoclonal antibody.

@en

type

label

Neutralization of divergent hu ...... p41 human monoclonal antibody.

@ast

Neutralization of divergent hu ...... p41 human monoclonal antibody.

@en

prefLabel

Neutralization of divergent hu ...... p41 human monoclonal antibody.

@ast

Neutralization of divergent hu ...... p41 human monoclonal antibody.

@en

P1433

Q35170702-0B17C3A6-E7E2-4C76-B70A-B2DAC2856132

P1476

Q35170702-8B30F026-539E-442A-BF1E-D60B594AF2AD

P2093

Q35170702-3A19E9BE-9D88-4642-ACB9-5CFDBE5D0006

Q35170702-45A2908F-7918-4419-96DF-335EC9C5DF1B

Q35170702-6228803D-680A-4993-9CDA-E3464BF5FD40

Q35170702-93520986-6991-4260-A031-8ABFFBD0FC17

Q35170702-A0844F0C-AB77-49EB-A584-C81AD7E9EC09

Q35170702-A64C89D0-4B66-4081-B730-060F79E0B571

Q35170702-B6067099-251B-4BB5-9ED2-33CD8E4B1DBF

Q35170702-BCEF052C-97C5-4C18-9E1F-0F80EBF731AE

P2860

Q35170702-0054EDC4-0AC9-4D04-808E-C8B22037A869

Q35170702-010E730E-8713-43F8-92C8-E32F24D99209

Q35170702-04C1ECDD-17F9-4AC9-BCDE-829CBD8B4F06

Q35170702-05296F88-A154-4145-B789-95851817ECFE

Q35170702-3B1AFD7E-757B-4FA4-B5A6-4C8D28DCBC7C

Q35170702-467BCDA8-07F4-498A-A70E-C98E1C3E3380

Q35170702-6DAF4E6E-2F52-445F-8FC5-C18754C7F79B

Q35170702-722C52BC-E2BD-4FB0-AC51-C6AE7BE6E3E6

Q35170702-79ADCF33-BDD3-4970-A3DE-363FF83A0DF7

Q35170702-88777F82-9A59-44D1-8650-D1CCF2EEBBC0

P304

Q35170702-A64388B3-C6F5-43A7-BF66-AFDBBA699033

P31

Q35170702-A2583D21-F508-4E58-A492-C9F40FD71B06

P356

Q35170702-194360F2-9B1D-4B99-922E-E7A12129EB95

P407

Q35170702-405CC4DE-DA96-4F32-B0A0-DCE3A4E8EEE9

P433

Q35170702-9CD61141-3A3A-4A1C-B05F-07C4C179AB19

P478

Q35170702-DBE71D85-E3A9-41DA-AB05-9088D949B805

P577

Q35170702-A7571535-59FC-4103-AFE3-057AAB4F7AB0

P5875

Q35170702-072B60BA-AD68-43D0-9AFA-47318C026121

P698

Q35170702-70F3CE97-0325-4523-BBE5-B4260B8330EB

P921

Q35170702-3631D0FC-A282-4B4B-B106-80B621B13CF5

P932

Q35170702-1A2542A2-4F79-4F05-9523-20FCE531932A

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Neutralization of divergent hu ...... p41 human monoclonal antibody.

@en

P2093

Arnold BA

http://www.w3.org/2001/XMLSchema#string

Boots LJ

http://www.w3.org/2001/XMLSchema#string

Conley AJ

http://www.w3.org/2001/XMLSchema#string

Emini EA

http://www.w3.org/2001/XMLSchema#string

Keller PM

http://www.w3.org/2001/XMLSchema#string

Kessler JA 2nd

http://www.w3.org/2001/XMLSchema#string

Shaw AR

http://www.w3.org/2001/XMLSchema#string

Tung JS

http://www.w3.org/2001/XMLSchema#string

P2860

Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1

Searching for peptide ligands with an epitope library.

Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain.

Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein

Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.

V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Tria

Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1

Proposed atomic structure of a truncated human immunodeficiency virus glycoprotein gp120 derived by molecular modeling: target CD4 recognition and docking mechanism.

Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody

P304

3348-3352

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.91.8.3348

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

91

http://www.w3.org/2001/XMLSchema#string

P577

1994-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

15685836

http://www.w3.org/2001/XMLSchema#string

P698

7512731

http://www.w3.org/2001/XMLSchema#string

P921

P932

43574

http://www.w3.org/2001/XMLSchema#string